In An Earth Day Test For Synthetic Biology Field, Zymergen Raises $500 Million In IPO
CLINTON PERRY PHOTOGRAPHY 2019
The past few years have been boom times for synthetic biology. Today, in a big test for public markets’ appetite for the emerging field, Zymergen raised $500 million in an initial public offering set to value the company at more than $3 billion.
“I love the symbolism that we’re going public on Earth Day,” cofounder and CEO Josh Hoffman told
Forbes in a morning video call. “There’s a bit of luck there, but I’m just super pleased. It is really cool.”
Hoffman, 50, a former McKinsey consultant and Rothschild merchant banker, founded Zymergen in 2013 with two former Amyris execs, Zach Serber, 46, now chief science officer, and Jed Dean, 43, now vp of of operations and engineering. They named it Zymergen as a mash-up of the words zymurgy (the study of fermentation), merge and genomics. Based in Emeryville, California, a hotspot for biology startups, the